A role of p53 in mediating epigenetic stress (RNA-Seq)
5-Azacytidine (Aza) and 5-Aza-2'-deoxycytidine (Dac) are the only epigenome modifying drugs in widespread clinical use, and are some of the primary therapeutics for Acute Myeloid Leukaemia treatment. The two are frequently used interchangeably, surprisingly as their selectivity of de-methylation is unique from the other, with to date no identified predictors of response or known biomarkers to indicate drug preference. Using these drugs to induce de-methylating conditions, we combine data from DRIPc-Seq, Immunostaining, RNA-Seq and Mass spectrometry with epigenetic analysis to uncover unique cellular responses following Aza and Dac treatment. Overall design: HEK293 cells were treated with 1.5µM of Azacitidine or Decitabine or solvent for 48 hours and RNA-seq was performed in three replicates to assess the change to the transcriptome.